 |
|
allopurinol
A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Zyloprim | | | | Foreign brand name: | | Sigapurol | | | | Abbreviations: | | 4'-HPP
ALLO | | | | Chemical structure names: | | - 1,5-dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one
- 1H-pyrazolo[3,4-d]pyrimidin-4-ol
- 4-hydroxypyrazolo[3,4-d]pyrimidine
| | |
| Previous: | allogeneic large multivalent immunogen melanoma vaccine LP2307, allogeneic LMP1-/LMP2- specific cytotoxic T-lymphocytes, allogeneic melanoma vaccine AGI-101H, allogeneic multipotent adult progenitor cells, allogeneic tumor cell vaccine | | Next: | aloe vera gel, Aloxi, alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine |
|
|
